Marlotamig

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameMarlotamig
Drug Alias NameAnti-EGFRxCD28 bispecific antibody - Regeneron PharmaceuticalsDalmitamigREGN-7075
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CD28
TargetsEpidermal growth factor receptor erbB1T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNsabp Foundation IncRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A